Our Work

Filter by:  
  • Use of Glucarpidase (Voraxaze®) to Treat Methotrexate Toxicity in Cancer Patients Associated with Lower Length-of-Stay and Mortality Rates

    Glucarpidase (Voraxaze®) is used to treat methotrexate (MTX) toxicity in patients with delayed MTX clearance due to impaired renal function. Using 2010-2017 Medicare claims data, KNG Health researchers assessed outcomes of glucarpidase patients relative to those experienced by patients treated for presumed MTX toxicity using other therapies. Researchers examined hospital length of stay (LOS), mortality, and readmission rates for Medicare cancer patients with delayed clearance of MTX treated with glucarpidase.  They found that Medicare cancer patients with presumed MTX toxicity receiving conventional treatment experience long hospitalizations, high intensive care unit (ICU) use and high mortality. Glucarpidase patients had lower LOS, inpatient mortality and 90-day mortality than the non-glucarpidase patients.  The study was published in ClinicoEconomics and Outcomes Research.

    Links: Publication

    Services : Health Economics & Outcomes Research Expertise: ,

    Glucarpidase (Voraxaze®) is used to treat methotrexate (MTX) toxicity in patients with delayed MTX clearance due to impaired renal function. Using 2010-2017 Medicare claims data, KNG Health researchers assessed outcomes of glucarpidase patients relative to those experienced by patients treated for presumed MTX toxicity using other therapies. Researchers examined hospital length of stay (LOS), mortality,

    More
  • New Medicare Payment Policy Resulted in Poorer Outcomes for Patients Severe Wounds

    In Fiscal Year (FY) 2016, Medicare began phasing in a dual payment system for long-term care hospitals (LTCHs) that would pay an LTCH differently for cases meeting criteria (“qualified” cases) and cases that did not meet criteria (“site-neutral” cases).  Under a fully implemented system, for LTCHs to meet criteria for a qualified case, a patient must have been discharged from a STACH immediately prior to the LTCH stay, and have spent at least 3 days in an intensive care unit during the STACH stay or received at least 96 hours of mechanical ventilation in the LTCH. For site-neutral cases, an LTCH will be paid the short-term acute care hospital (STACH) amount or its costs, whichever amount is lesser.

    LTCHs, which treat chronically critically ill and medically complex patients who require hospital-level care for extended periods, are a particularly important care setting for severe wound patients. Medicare Fee-for-Service patients hospitalized with severe wounds in 2015 were six times more likely to be discharged to an LTCH compared to all Medicare discharges (7.1% vs 1.2%).  In FY 2015, 54% of severe wound patients treated in LTCHs would not have met criteria, and LTCHs treating these patients would have been at risk of receiving payment reductions between 20–40% for these cases during the phase-in period.

    KNG Health researchers developed a difference-in-difference model to examine the effects of the recent changes in the LTCH Medicare payment policy on treatment patterns and outcomes for site-neutral severe wound patients.  The findings, published in the Journal of Medical Economics, show that the new patient criteria for LTCHs were associated with fewer site-neutral severe wound cases going to LTCHs, and higher readmissions and post-discharge sepsis.

    Links: Publication

    Services : Health Economics & Outcomes Research, Payment Policy & Delivery System Innovation, Practice Area - Healthcare Reform and Payment Innovation Expertise: , ,

    In Fiscal Year (FY) 2016, Medicare began phasing in a dual payment system for long-term care hospitals (LTCHs) that would pay an LTCH differently for cases meeting criteria (“qualified” cases) and cases that did not meet criteria (“site-neutral” cases).  Under a fully implemented system, for LTCHs to meet criteria for a qualified case, a patient

    More
  • The Effects of Calcitonin Gene-Related Peptide Inhibitors on Migraine Days, Healthcare Use, and Workplace Productivity: A Markov Model Approach

    Migraine is a debilitating condition in which painful headaches occur frequently.  Treatments for migraines, such as acute care treatment and preventive therapy, can help migraine sufferers manage their pain and reduce their frequency. However, there have been few recent improvements in the market for preventive migraine therapies.  Calcitonin gene-related peptide (CGRP) inhibitors are a new class of preventive migraine drugs that may address the need for new, effective treatments for migraines.

    In this study, we estimate the value of CGRP inhibitor treatment for chronic and episodic migraine sufferers. We used a Markov model framework with four primary outcomes: (1) migraine days; (2) acute care drug treatment days; (3) number of physician and emergency room visits; and (4) workplace productivity.  We considered the impact of CGRP inhibitors on patients who are not currently on preventive therapy because existing non-CGRP inhibitor treatments are ineffective or intolerable for these patients.

    Use of CGRP inhibitors was on average associated with fewer migraine days per year (-18.68/-29.20 for EM/CM), fewer triptan uses per year (-3.21/-5.04), more physician visits for migraine per year (1.03/1.02), fewer ER visits per year (-0.06/-0.10), higher probability of full-time (0.03/0.02) and part-time employment (0.01/0.00), fewer lost productive hours per year (-39.69/-21.31), and less indirect cost per year (-$20,327/-$11,176). Effects were generally greater for individuals with higher response to the drugs and varied by age and sex.

    If all migraine sufferers not on preventive medicine used CGRP inhibitors, we estimate national indirect cost savings of $390 billion for EM and $6 billion for CM over 10 years, as well as national reductions in migraine days per year of 358 million for EM and 16 million for CM.

    Links: Report

    Services : Health Economics & Outcomes Research Expertise:

    Migraine is a debilitating condition in which painful headaches occur frequently.  Treatments for migraines, such as acute care treatment and preventive therapy, can help migraine sufferers manage their pain and reduce their frequency. However, there have been few recent improvements in the market for preventive migraine therapies.  Calcitonin gene-related peptide (CGRP) inhibitors are a new

    More
  • Quality Measure Development and Assessment for Ambulatory Surgery Centers

    KNG Health provides statistical support to The Ambulatory Surgery Center Quality Collaboration (ASC QC) to evaluate quality measures proposed for inclusion in CMS’ ASC Quality Reporting Program.  KNG Health has conducted statistical evaluation of select measures in terms of reliability, validity, feasibility, and interpretability based on data collected through pilot testing.  As part of its quality measure work for ASC QC, KNG Health has also developed a data collection tool for measure reliability testing, which included automation and consistency checks to minimize data entry error.  In addition, KNG Health has analyzed data from Culture of Patient Safety Survey data from ambulatory surgery centers and developed both facility-level and organizational-level reports that use data visualization tools to illustrate analysis results.

    Services : Program Evaluation and Monitoring Expertise:

    KNG Health provides statistical support to The Ambulatory Surgery Center Quality Collaboration (ASC QC) to evaluate quality measures proposed for inclusion in CMS’ ASC Quality Reporting Program.  KNG Health has conducted statistical evaluation of select measures in terms of reliability, validity, feasibility, and interpretability based on data collected through pilot testing.  As part of its

    More
  • Comparative Outcome and Market Analyses for Long Term Acute Care Hospitals

    KNG Health was contracted by a long-term care hospital (LTCH) to conduct a series of studies to better understand (1) the value of care provided by the hospital to patients in its market area; (2) the value it provides to short term acute care hospitals, and (3) referral patterns in its market.  To address these objectives, KNG Health conducted a series of studies using Medicare claims data.  In the first study, we compared mortality, readmissions, discharge to community, and Medicare spending per beneficiary between patients treated in the client’s LTCH to similar patients treated in other LTCHs and skilled nursing facilities (SNFs) in the same market area.  We used propensity score matching to construct a comparison group of patients who have similar clinical characteristics to the population of the LTCH examined.  In the second study, we conducted a market analysis that identifies the referral patterns among patient discharged from short-term acute care hospitals in the LTCH’s market area.  This analysis revealed the LTCH’s market share among cases that fulfill LTCH patient criteria as well as the share of cases that are referred to other providers.  The analysis was conducted for cases that fulfilled LTCH patient criteria, and the results were presented separately by MS-DRG.  In the third study, we predict cost savings that short-term acute care hospitals can experience by transferring their cases to the LTCH earlier.  We estimate a predictive model of average hospital costs and use the model’s results to predict cost savings under different counterfactual scenarios regarding length of stay.  The findings are incorporated into an interactive Excel tool that allows the user to identify predictions for different MS-DRGs and length of stays.

    Services : Health Economics & Outcomes Research Expertise: , ,

    KNG Health was contracted by a long-term care hospital (LTCH) to conduct a series of studies to better understand (1) the value of care provided by the hospital to patients in its market area; (2) the value it provides to short term acute care hospitals, and (3) referral patterns in its market.  To address these

    More
  • The Effectiveness of Glucarpidase in Treating Methotrexate Toxicity: A Retrospective Study

    KNG Health conducted a retrospective cohort study of Medicare beneficiaries to examine the effectiveness of glucarpidase in cancer patients.  Glucarpidase is a drug that is used to treat toxicity that can be caused by methotrexate, an anticancer and immunosuppressive agent.  We used Medicare claims data to compare the outcomes between cancer patients treated with glucarpidase and similar patients treated with dialysis.  In constructing the comparison group, we identified patients who are likely to be candidates for glucarpidase based on clinical indicators in the Medicare claims data.  Further risk adjustment was conducted using Elixhauser comorbidities and inverse probability of treatment weighting estimation.  Outcomes examined included length of stay in hospital, number of days in intensive care unit, mortality, and readmission rate.  The findings are presented in a research manuscript, which is currently under review at a peer-reviewed journal.

    Services : Health Economics & Outcomes Research Expertise: ,

    KNG Health conducted a retrospective cohort study of Medicare beneficiaries to examine the effectiveness of glucarpidase in cancer patients.  Glucarpidase is a drug that is used to treat toxicity that can be caused by methotrexate, an anticancer and immunosuppressive agent.  We used Medicare claims data to compare the outcomes between cancer patients treated with glucarpidase

    More

More Research